Author:
Sunami Kuniko,Naito Yoichi,Aimono Eriko,Amano Toraji,Ennishi Daisuke,Kage Hidenori,Kanai Masashi,Komine Keigo,Koyama Takafumi,Maeda Takahiro,Morita Sachi,Sakai Daisuke,Kohsaka Shinji,Tsuchihara Katsuya,Yoshino Takayuki
Abstract
Abstract
Background
Since June 2019, cancer genomic profiling (CGP) tests have been reimbursed by the National Health Insurance system in Japan, with restrictions for government-designated hospitals with a molecular tumor board composed of multidisciplinary specialists, known as an expert panel (EP). The standardization of EPs is a critical challenge for implementing precision oncology in the clinical setting.
Methods
Data on consecutive cases who underwent the CGP tests at 11 core hospitals between June 2019 and January 2020 were collected. We evaluated the proportions of cases that received genomically matched treatments, including investigational new drugs (INDs) based on CGP results, and/or for which genetic counseling was recommended. Two simulated cases were annotated by each EP. The annotated reports were then centrally assessed.
Results
Each EP mainly discussed the applicability to genomically matched treatments and the necessity of performing genetic counseling. A pre-review of the report by key members in each EP reportedly made the EP conference more interactive and efficient, and thereby saved time. A total of 747 cases underwent CGP tests, 28 cases (3.7%) received genomically matched treatment, and 17 cases (2.3%) were referred for genetic counseling. Annotated reports for the simulated cases varied across the EPs, particularly the number of recommended IND trials, which seemed to be associated with the actual number of participants in IND trials.
Conclusions
This investigation provides reference data for the application of precision oncology in a clinical setting. Further investigations on the standardization of clinical annotations are warranted.
Funder
Ministry of Health, Labour and Welfare
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Reference39 articles.
1. National Comprehensive Cancer Network Guidelines (2020). https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed Aug 2020
2. El-Deiry WS, Goldberg RM, Lenz HJ et al (2019) The current state of molecular testing in the treatment of patients with solid tumors. CA Cancer J Clin 69:305–343
3. Yoshino T, Arnold D, Taniguchi H et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44–70
4. The OncoGuide™ NCC oncopanel system receives insurance coverage for use in cancer genome profiling. https://www.sysmex.co.jp/en/news/2019/190531.html. Accessed Aug 2020
5. Chugai Launches Genomic Mutation Analysis Program, FoundationOne CDx Cancer Genomic Profile. https://www.chugai-pharm.co.jp/english/news/detail/20190603150001_625.html. Accessed Aug 2020